Current Issue
Volume: 38
Number: 4
Index: December 2010
Clinical Focus:Respiratory Care
Editorial Calendar
December 2010
Clinical Focus: Respiratory Medicine
  • Asthma and the athlete
    • Vocal cord dysfunction
    • Exercise-induced asthma
    • Exercise-induced bronchospasm
  • COPD
    • Obesity and COPD
    • Relationship between COPD and nutrition intake
  • Treatment options for steroid-induced osteoporosis in men
  • Treatments for asthma
    • Bronchodilators, anticholinergics
    • Corticosteroids
    • Metered-dose vs other types of inhalers
  • Respiratory infections in winter sports athletes
  • Asthma in elite athletes
  • Pulmonary rehabilitation and physical activity
  • Fitness and long-term oxygen therapy/lung transplantation
  • Airflow function and the metabolic syndrome
View More
Submission deadline: November 05
Fast-Track deadline: November 15
Fast-Track peer review is available for those papers requiring immediate review (for an additional fee). Complete peer review is finalized in 1-2 weeks and comments are provided to the author within 72 hours of their receipt by the editorial office. Authors are asked to submit a revised manuscript within 10-12 days. Accepted manuscripts are processed within 2-3 weeks, published online within 3 business days of final author approval, and in print in the next available issue.
Submit your FAST-TRACK manuscript online today. It's fast, it's easy! Just follow the detailed instructions, fill in all the required fields, and upload your manuscript.
Get started NOW!
[email protected]

[email protected]

[email protected]

[email protected]

Document Delivery Services

[email protected]

[email protected] [email protected]

[email protected]

Managing Director:
John Elduff
Phone: 610-889-3732
Fax: 1-866-297-3168
[email protected]

General Information
Phone: 610-889-3730
Fax: 1-866-297-3168
1235 Westlakes Drive
Suite 320
Berwyn, PA 19312
doi: 10.3810/psm.2010.06.1781
The Physician and Sportsmedicine: Volume 38: No.2
Hylan G-F 20 Improves Hip Osteoarthritis:
A Prospective, Randomized Study
Andrew I. Spitzer, MD; Barry I. Bockow, MD; Victoria A. Brander, MD; James W. Yates, MD; Daryl K. MacCarter, MD; Garland K. Gudger, MD; Stephanie Haller, MD; Stephen L. Lake, MD; And Daniel B. Magilavy, MD
Abstract: We compared the efficacy and safety of intra-articular hylan G-F 20 with methylprednisolone acetate (MPA) for treating symptomatic Kellgren-Lawrence grade (KLG) 2 or 3 hip osteoarthritis in a prospective, randomized, multicenter, double-blind trial (N = 313). Two injections of hylan G-F 20 were administered 2 weeks apart (n = 150), or 1 injection of 40 mg MPA and 1 sham injection 2 weeks later (n = 155). The Western Ontario and McMaster Universities Arthritis Index (WOMAC) (total and subscale), clinician observations, and patient global assessments were collected at baseline and at weeks 4, 8, 12, 16, 20, and 26 (intent-to-treat population was analyzed; n = 305). Responder rates were assessed by WOMAC domain A, and criteria were established by the Outcome Measures in Rheumatology Clinical Trials–Osteoarthritis Research Society International (OMERACT-OARSI). At week 26, WOMAC A improved by 16.6 mm for hylan G-F 20 versus 13.6 mm for MPA. Response rates were higher with hylan G-F 20 versus MPA in patients with more advanced disease (KLG 3) and were similar between hylan G-F 20 and MPA in patients with less advanced disease (KLG 2). Adverse events were similar between groups and between patients with KLG 2 or 3. Hylan G-F 20 provided clinically meaningful improvements in pain and function, comparable with those of MPA, with good safety and tolerability. Thus, we conclude it is an appropriate option for treating hip osteoarthritis.

Keywords: corticosteroid; hip; hyaluronan; hylan G-F 20; methylprednisolone acetate; osteoarthritis


Back to the table of contents for the June 2010 issue